Skip to main content
Signal8
Launch Terminal

Decoy Therapeutics Inc. (DCOY)

Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Decoy Therapeutics Inc. logo

Decoy Therapeutics Inc.

NASDAQ:DCOYHealthcare
-13.01%$1.07
AH$1.08+0.93%vs close
Mkt Cap$2.55M
Float2.25M
O/S2.39M
Vol
$ Vol
RVOL
Inst Own0.2%
SI4.3%
Earnings
Dilution
Decoy Therapeutics Inc. logoNASDAQ:DCOY$1.07-13.01%
Phase Distribution
8 lead-sponsored trials·0 active·1 completed
Early Phase 11
Phase 12
Phase 1/23
Phase 22
(1 more as collaborator)
Status Overview
Not yet recruiting1
Completed1
Stopped4
Unknown2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 2
    Terminated

    A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps.

    FLX-787-ODT (orally disintegrating tablet), Placebo ODT

    Motor Neuron Disease

    Enrollment
    54
    Start
    Jul 2017
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT03196375
  • Phase 2
    Terminated

    A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps.

    FLX-787-ODT (orally disintegrating tablet), Placebo ODT

    Charcot-Marie-Tooth Disease

    Enrollment
    27
    Start
    Oct 2017
    Primary Completion
    Jul 2018
    Completion
    Jul 2018
    NCT03254199
  • Phase 1/2
    Terminated

    Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

    FLX-787-ODT

    Amyotrophic Lateral Sclerosis, Fasciculation

    Enrollment
    3
    Start
    Apr 2018
    Primary Completion
    Aug 2018
    Completion
    Aug 2018
    NCT03334786
  • Phase 1/2
    Withdrawn

    Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS

    FLX-787-ODT (orally disintigrating tablet)

    Amyotrophic Lateral Sclerosis, Fasciculation

    Enrollment
    0
    Start
    Nov 2017est.
    Primary Completion
    Aug 2018est.
    Completion
    Aug 2018est.
    NCT03338114
  • Phase 1/2
    Unknown status

    A Rollover Protocol to Allow for Continued Access to the LSD1 Inhibitor Seclidemstat (SP-2577)

    Seclidemstat

    Ewing Sarcoma, Myxoid Liposarcoma +7

    Enrollment
    10
    Start
    Jan 2022
    Primary Completion
    Dec 2025est.
    Completion
    Dec 2025est.
    NCT05266196
  • Phase 1
    Unknown status

    Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

    Seclidemstat, Cyclophosphamide

    Ewing Sarcoma, Myxoid Liposarcoma +9

    Enrollment
    50
    Start
    Jun 2018
    Primary Completion
    Sep 2025est.
    Completion
    Dec 2025est.
    NCT03600649
  • Phase 1
    Completed

    Phase 1 Trial of the LSD1 Inhibitor SP-2577 (Seclidemstat) in Patients With Advanced Solid Tumors

    SP-2577 Seclidemstat

    Advanced Solid Tumors

    Enrollment
    23
    Start
    Jun 2019
    Primary Completion
    Apr 2021
    Completion
    Apr 2021
    NCT03895684
  • Early Phase 1
    Not yet recruiting

    Study of SP-3164 in Relapsed or Refractory Non-Hodgkin's Lymphoma

    SP-3164

    Lymphoma, Non-Hodgkin's, Adult

    Enrollment
    72
    Start
    Mar 2024est.
    Primary Completion
    Aug 2025est.
    Completion
    Aug 2027est.
    NCT05979857
Search ClinicalTrials.gov for “Decoy Therapeutics”